Holen Sie sich die Stockscreener-App
79.72
2.22%
-1.81
Vorhandelsmarkt:
81.51
1.79
+2.25%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt EW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$81.53
Offen:
$81.53
24-Stunden-Volumen:
6.21M
Relative Volume:
1.29
Marktkapitalisierung:
$45.96B
Einnahmen:
$6.07B
Nettoeinkommen (Verlust:
$1.06B
KGV:
44.13
EPS:
1.8063
Netto-Cashflow:
$1.34B
1W Leistung:
+0.85%
1M Leistung:
-2.80%
6M Leistung:
+4.17%
1J Leistung:
+13.14%
1-Tages-Spanne:
$79.19
$82.00
1-Wochen-Bereich:
$78.79
$82.49
52-Wochen-Spanne:
$72.30
$87.89
Edwards Lifesciences Corp Stock (EW) Company Profile
Firmenname
Edwards Lifesciences Corp
Sektor
Branche
Telefon
(949) 250-2500
Adresse
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
79.72 | 45.96B | 6.07B | 1.06B | 1.34B | 1.8063 |
ABT
Abbott Laboratories
|
92.48 | 161.12B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
329.65 | 125.35B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
83.79 | 105.28B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
65.69 | 88.46B | 20.62B | 3.56B | 3.66B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-01 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2026-01-09 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-12-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Hochstufung | Jefferies | Hold → Buy |
| 2025-10-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-04-24 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Stifel | Hold → Buy |
| 2025-01-16 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-31 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | Truist | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-02-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-28 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-03-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Herabstufung | Bernstein | Outperform → Underperform |
| 2023-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Herabstufung | Stifel | Buy → Hold |
| 2022-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Eingeleitet | Mizuho | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-29 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-27 | Bestätigt | Citigroup | Buy |
| 2022-01-27 | Bestätigt | Evercore ISI | Outperform |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Buy |
| 2022-01-27 | Bestätigt | UBS | Neutral |
| 2021-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-30 | Bestätigt | Deutsche Bank | Hold |
| 2021-07-30 | Bestätigt | Jefferies | Buy |
| 2021-07-30 | Bestätigt | Morgan Stanley | Overweight |
| 2021-07-30 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-30 | Bestätigt | Stifel | Buy |
| 2021-07-30 | Bestätigt | UBS | Neutral |
| 2021-07-30 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-04-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-11 | Bestätigt | Canaccord Genuity | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Underperform |
| 2020-04-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-09-23 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-24 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-18 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Hold |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-10-02 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Herabstufung | Guggenheim | Buy → Neutral |
Alle ansehen
Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten
Edwards Lifesciences Corp (EW) Q1 2026 Earnings Call Highlights: - GuruFocus
Edwards Lifesciences Q1 Earnings Call Highlights - MarketBeat
Edwards Lifesciences reports Q1 EPS 78c, consensus 73c - TipRanks
Earnings call transcript: Edwards Lifesciences Q1 2026 beats expectations By Investing.com - Investing.com Australia
Transcript: Edwards Lifesciences Q1 2026 Earnings Conference Call - Benzinga
Edwards Lifesciences (EW) Raises FY26 Sales Growth Guidance - GuruFocus
Is Edwards Lifesciences (EW) Still 13.6% Undervalued After Q1 20 - GuruFocus
Edwards Lifesciences Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Edwards Lifesciences (NYSE:EW) Releases Q2 2026 Earnings Guidance - MarketBeat
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Edwards Lifesciences options imply 5.2% move in share price post-earnings - TipRanks
Edwards Lifesciences (EW) Stock Rises on Q1 2026 Earnings - Quiver Quantitative
Edwards Lifesciences shares rise 4% as guidance raised following Q1 earnings beat - Investing.com Canada
Edwards Lifesciences Q1 Earnings, Revenue Rise - marketscreener.com
Edwards Lifesciences (NYSE:EW) Releases Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
Edwards Lifesciences reports Q1 revenue $1.65B, raises 2026 sales and adjusted EPS guidance - TradingView
Stronger Q1 boosts 2026 outlook for Edwards Lifesciences (NYSE: EW) - Stock Titan
Heart-valve demand drives Edwards to raise 2026 forecast - Stock Titan
Edwards Lifesciences Reports First Quarter Results - ChartMill
Edwards Lifesciences earnings on deck as TAVR share gains loom - Investing.com
Edwards Lifesciences Corp. Experiences Valuation Adjustment Amid Competitive Market Landscape - Markets Mojo
Universal Beteiligungs und Servicegesellschaft mbH Acquires 21,165 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
EW Technical Analysis | Trend, Signals & Chart Patterns | EDWARDS LIFESCIENCES CORP (NYSE:EW) - ChartMill
Edwards Lifesciences' Q1 Earnings on Deck: Here's What to Expect - Yahoo Finance
TriaGen Wealth Management LLC Invests $4.55 Million in Edwards Lifesciences Corporation $EW - MarketBeat
Mirae Asset Global Investments Co. Ltd. Increases Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp. Experiences Valuation Adjustment Amidst Market Dynamics and Performance Metrics - Markets Mojo
Birch Hill Investment Advisors LLC Sells 13,385 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation $EW Shares Sold by Ninety One UK Ltd - MarketBeat
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
TD Cowen reiterates Edwards Lifesciences stock rating on TAVR strength By Investing.com - Investing.com South Africa
TD Cowen reiterates Edwards Lifesciences stock rating on TAVR strength - Investing.com
KBC Group NV Reduces Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Lbp Am Sa Buys 107,330 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Fisher Funds Management LTD Decreases Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences to Host Earnings Conference Call on April 23, 2026 - marketscreener.com
Edwards Lifesciences Corporation $EW Stock Position Lessened by Diversify Advisory Services LLC - MarketBeat
Edwards Lifesciences Hits Day Low of $79.06 Amid Price Pressure - Markets Mojo
Edwards Lifesciences (EW) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Hardman Johnston Global Advisors LLC Sells 34,124 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Growth Report: Will Edwards Lifesciences Corporation outperform its industry peersWatch List & Fast Moving Stock Watchlists - baoquankhu1.vn
Edwards Lifesciences’ CFO Ullem sells $1m in shares - Investing.com UK
Edwards Lifesciences Corp (EW) Stock Down 3.1% -- Now Undervalued? GF Score: 98/100 - GuruFocus
Edwards Lifesciences (NYSE: EW) CFO trades 13K shares under 10b5-1 plan - Stock Titan
Edwards Lifesciences Tops $430 Million Daily Turnover Amid Earnings Miss and Valuation Squeeze - Bitget
Edwards Lifesciences Corp. stock rises Wednesday, still underperforms market - MarketWatch
Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $97 From $95, Maintains Buy Rating - marketscreener.com
Sivik Global Healthcare LLC Acquires New Shares in Edwards Lifesciences Corporation $EW - MarketBeat
Rathbones Group PLC Has $1.42 Million Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Insider Sell: Daniel Lippis Sells Shares of Edwards Lifesciences Corp (EW) - GuruFocus
Finanzdaten der Edwards Lifesciences Corp-Aktie (EW)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):